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The Marfan syndrome is an autosomal dominant heritable
disease of connective tissue whose skeletal features were
first described in 1896 (1) . Cardiovascular complications,
which largely determine longevity, were not recognized until
the mid 1940s . Clinical diagnostic criteria were refined in
1979 by Pyeritz and McKusick ( ), who focused on the
familial, ocular, skeletal and cardiovascular abnormalities .
The overt expressions of the Marfan gene vary widely, and
the incidence of the disorder is likely to be considerably
higher than currently recognized (4 to 6 cases/100,000) ( ) .
Because of the variability of expression, the clinical diagno-
sis may be open to question even after refined diagnostic
investigation or, conversely, the diagnosis may be obvious at
a glance .
The present study . The mean age at death is the mid 30s
and is largely a reflection of the presence and degree of
cardiovascular involvement (3) . In this issue of the Journal,
Marsalese et al . (4) provide us with important insights into
the natural and postoperative histories of a sizable number of
patients with the Marfan syndrome . They confirm the central
role of cardiovascular involvement as a determinant of
longevity and report encouraging information on improved
survival using current techniques of composite graft replace-
ment of the ascending aorta and aortic valve with reimplan-
tation of the coronary arteries in contrast to the older
procedure of end to end anastomosis after resection of the
aortic aneurysm (5,6) .
Marsalese et al . (4) advocate early detection of cardiac
involvement and consider close serial follow-up to be critical
to patient care . Because their study was retrospective (1959
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to 1987), only 56% of their patients underwent angiography,
only half underwent echocardiography and none had nuclear
magnetic resonance (NMR) imaging . Importantly, the stan-
dard chest radiograph may be deceptively unimpressive
when aortic root dilation is confined to the sinuses of
Valsalva and proximal ascending aorta. Echocardiography
and NMR imaging provide precise comparative measure-
ments of the aortic root size, which is the principal basis for
selecting patients for relatively early aggressive surgical
intervention . In addition, echocardiography with Doppler
interrogation and color flow imaging have been major diag-
nostic steps forward in shedding light on involvement of the
mitral apparatus in Marfan's syndrome (see later), an impor-
tant topic that Marsalese et al (4) deal with little if at all .
Diagnostic criteria . The first necessity is to establish the
diagnosis of the Marfan syndrome on the basis of four major
criteria-the family history and the ocular, musculoskeletal
and cardiovascular features . Family history and muscu-
loskeletal involvement can be identified with the unaided
senses, recognition of ocular manifestations (ectopia lentis)
often requires slit-lamp examination, but involvement of the
aortic root or mitral apparatus, or both, may not be evident
at the bedside and their detection may depend instead on
echocardiography and NMR imaging . In the University of
California, Los Angeles Marfan Registry, rigorous diagnos-
tic criteria for the diagnosis require that a patient with a
positive family history have at least two of the major criteria
(cardiovascular, ocular, skeletal) or, in the absence of a
positive family history, have characteristic cardiovascular
involvement and at least one of the other two major criteria .
In the classic Marfan syndrome the musculoskeletal mani-
festations are readily evident, the ocular manifestations
sometimes identified with nothing more than a pocket flash-
light and the cardiovascular involvement evident on physical
examination and echocardiographic or NMR imaging, or
both. The problem arises when a patient with no family
history presents with isolated ectopia lentis or isolated
kyphoscoliosis, pectus carinatum or excavatum or ligamen-
tal laxity . By "isolated" we mean absence of echocardio-
graphic, Doppler or NMR imaging evidence of aortic root or
mitral apparatus involvement . We believe that such patients
should not be cast under the diagnostic cloud of a "forme
fruste" of the Marfan syndrome . If the aortic root and mitral
apparatus are normal, the cloud should be removed and the
patient reassured. An interesting variation on the theme is
"annulo-aortic ectasia," which can result in dissection of the
ascending aorta in the absence of a family history of the
Marfan syndrome and without ectopia lentis or musculoskel-
etal/ligamental abnormalities .
Treatment policy . In patients who meet the diagnostic
criteria for the Marfan syndrome, comparative assessment
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of aortic root size is pivotal because of potentially cata-
strophic aortic dissection or rupture . Once the aortic root
diameter reaches 50 mm, it is our policy to reassess the
dimension quarterly . There is a general consensus that an
aortic root dimension ?60 mm dictates anticipatory (prophy-
lactic) surgery, a position that Marsalese et al . (4) recom-
mend with data to support that contention . In this category,
the risk is high if surgery is not performed, but the risk of
surgical intervention by current techniques carries a mortal-
ity rate of <5% . What of the Marfan patient with an aortic
root dimension that is increased but <50 mm? An important
but unanswered question concerning patients in this cate-
gory is whether beta-adrenergic blockade is beneficial . Such
therapy has been advocated because of presumed beneficial
effects in retarding aortic root dilation (7,8), and Marsalese
et al . (4) recommend it for their Marfan patients who have
evidence of aortic root dilation and for their surgical patients
before and after operation . They hasten to remind us that
belief in the efficacy of this treatment is not based on results
of controlled clinical trials that are currently available . In
any event, such patients should be advised to avoid abrupt,
strenuous or isometric exercise (9) .
Role of mitral valve involvement . Marsalese et al . (4) do
not deal with involvement of the mitral apparatus . Careful
auscultatory assessment with physical interventions to-
gether with echocardiographic-Doppler interrogation and
color flow imaging are obligatory in this regard, the former
focusing on the chordae tendineae, the leaflets and the
annulus (10-1 ). It has been suggested that >80% of patients
with the Marfan syndrome have "mitral valve prolapse,"
but the echocardiographic criteria on which this conclusion
was based were less strict (13-19) than those currently
advocated (10-1 ) .
Importantly, in children with Marfan's syndrome, cardiac
involvement is more likely to take the form of mitral regur-
gitation-often severe-than of clinically overt aortic root
disease (18) . Because of the morphology of the mitral
apparatus in children with the Marfan syndrome and mitral
regurgitation, valve reconstruction rather than replacement
is often feasible . Older children with aortic root involvement
should be sequentially reassessed, as is recommended for
adults. It is worth restating that, although adults may have
surgically important mitral or aortic regurgitation, the most
important life-threatening complication is progressive aortic
root dilation with dissection or rupture .
Antibiotic prophylaxis and anticoagulant therapy . Pro-
phylaxis for infective endocarditis is obligatory in the pres-
ence of mitral or aortic regurgitation, and postoperatively in
the presence of an aortic prosthesis . Postoperative antico-
agulation depends on the type of prosthesis . After a com-
posite graft and aortic prosthesis, annual assessment of the
entire thoracic aorta by NMR imaging is advocated ( 0) . The
mitral apparatus and left ventricular function require contin-
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ued surveillance, which is best done by echocardiography
with Doppler interrogation and color flow imaging .
Genetic counseling . Genetic counseling is an important
issue in patients with the Marfan syndrome . First degree
relatives should undergo echocardiographic screening of the
aortic root and mitral apparatus. Women who have the
Marfan syndrome and who are in the childbearing years
confront two major risks : 1) the immediate maternal risk of
pregnancy ; and ) the 50% chance of transmitting the Marfan
syndrome to offspring. There is a general consensus that any
degree of aortic root dilation in a patient meeting the
diagnostic criteria for the Marfan syndrome materially in-
creases the risk of pregnancy . The role of beta-blocker
therapy in this setting is not established . It is also not clear
whether women who have had insertion of a composite graft
and aortic prosthesis confront pregnancy with an acceptably
lower risk . Anticoagulants in this context represent a signif-
icant risk to the fetus .
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